FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 Diabetes

STRATEGIC NEWS WATCH — August 28, 2026

The FDA cleared Mounjaro to cut cardiovascular risk in type 2 diabetes, but on an 8% edge over Lilly’s own Trulicity rather than a placebo-controlled win. AstraZeneca and Ionis’ eplontersen missed in ATTR cardiomyopathy, dragging Alnylam down and reopening whether RNA silencers add anything on top of stabilizers.

Today’s top developments:

The FDA expanded the label for Eli Lilly’s Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in at-risk adults with type 2 diabetes — on the strength of the 13,000-patient, four-year SURPASS-CVOT trial, which showed an 8% lower rate of cardiovascular death, heart attack or stroke against Lilly’s own Trulicity rather than placebo (Fierce Pharma)
AstraZeneca and Ionis’ eplontersen failed to significantly cut cardiovascular events or death in the CARDIO-TTRansform trial in transthyretin amyloid cardiomyopathy — 29% of patients had an event versus 32% on placebo — sending Alnylam down 5% at open as analysts questioned whether TTR silencers add benefit once a stabilizer is on board (BioPharma Dive)
A reconstruction of how Merck and Moderna’s intismeran autogene cracked the century-old cancer-vaccine problem located the difference in breadth — 34 patient-specific neoantigens per shot alongside Keytruda — though the Phase 3 INTerpath-001 hazard ratio in resected melanoma remains unpublished (Reuters)
Bankrupt BioXcel Therapeutics agreed a stalking-horse deal under which Teva would buy substantially all its assets for $57.5 million up front plus up to $67.5 million in milestones — up to $125 million — with the real prize an orally dissolving dexmedetomidine film carrying a November 14, 2026 PDUFA date (Fierce Pharma)
Genentech licensed DualityBio’s Dupac antibody-drug conjugate platform for $45 million up front and up to $1 billion in milestones plus tiered royalties, buying next-generation payload chemistry engineered to overcome resistance rather than named assets (Pharmaceutical Executive)

What to Watch

Intismeran’s hazard ratio — No effect size has been released for INTerpath-001, yet U.S. approval could come as early as 2027. With Citi’s bar at 0.72 or lower for a positive result and 0.65 or lower for a clear win, the medical-conference presentation, not the topline, decides whether the filing and the valuation hold.
Silencer class read-through — CARDIO-TTRansform had 81% of patients on a stabilizer against 53% in Alnylam’s HELIOS-B. The open question is whether Alnylam publishes subgroup data isolating stabilizer-treated patients — the only clean test of whether vutrisiran’s additive benefit survives the comparison.
BXCL501’s November 14 PDUFA — Up to $67.5 million of Teva’s $125 million bid is milestone-contingent, and the FDA decision lands after the bankruptcy auction. The signals to track are the auction schedule and whether a rival bidder emerges before that decision de-risks the asset.
Novo’s response on cardiovascular data — Mounjaro’s label came from an active-comparator trial with an 8% margin, not placebo-controlled superiority. The question is whether Novo Nordisk presses that distinction with payers, and whether either company runs a genuine head-to-head against semaglutide.
BioCryst’s two deals in 18 months — With internal discovery shuttered since June 2026, business development is now BioCryst’s only source of new assets. Whether the stated target of two licensed programmes is met — and at what stage and price — is the marker to track.

This brief highlights the edition’s top stories. Read the full August 28, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.

Related Stories

FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis

FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer

FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease